Commenced the U.S. commercial launch of Symvess for extremity vascular injury in the first quarter of 2025, following full FDA approval on December 19, 2024. Generated $1.4 million in product revenue for the year ended December 31, 2025, marking the company's first commercial sales. Reported a net loss of $40.8 million for the year ended December 31, 2025, a significant reduction from $148.7 million in 2024, primarily due to non-cash gains from fair value remeasurements. Operating losses were $108.1 million in 2025, compared to $114.4 million in 2024. Cash and cash equivalents stood at $50.5 million as of December 31, 2025. Substantial doubt exists about the company's ability to continue as a going concern beyond one year without generating sufficient cash flows from commercial sales or obtaining additional capital. Positive topline results from the V007 Phase 3 trial for AV access in hemodialysis were reported in August 2024, meeting co-primary endpoints. Two-year results from the V007 trial, presented in November 2025, showed superior duration of access for ATEV in female, obese, and diabetic patients compared to AV fistula. An ongoing V012 Phase 3 trial is assessing ATEV for AV access in hemodialysis in women, with interim analysis expected in Q2 2026. Plans to submit a supplemental Biologics License Application (BLA) for ATEV for AV access for hemodialysis in the second half of 2026, targeting high-risk patient subgroups. Preclinical results for the coronary tissue engineered vessel (CTEV) in a baboon model for coronary artery bypass grafting (CABG) were published in September 2025, demonstrating sustained patency, recellularization, and adaptive remodeling. Preclinical study results for CTEV as a modified Blalock-Taussig-Thomas (mBTT) shunt in pediatric heart surgery were published in October 2023, showing patency, structure, and blood flow. Secured a $77.5 million senior secured term loan facility in December 2025, with an initial $40.0 million funded to repay previous debt obligations. Completed a registered direct offering on March 20, 2026, raising approximately $18.4 million in net proceeds. Received a minimum purchase commitment of approximately $1.48 million for Symvess in the Kingdom of Saudi Arabia, with ongoing negotiations for a joint venture and license. Filed a Marketing Authorization Application (MAA) for Symvess in the vascular trauma indication with the Ministry of Health of the State of Israel on March 16, 2026. Implemented a workforce reduction of 30 employees in April 2025 as part of cost-saving measures. Multiple ongoing legal proceedings, including a putative securities class action lawsuit and several stockholder derivative actions, allege false or misleading statements and breaches of fiduciary duty.